Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04042558
Title A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Centre Francois Baclesse
Indications

lung non-squamous non-small cell carcinoma

Therapies

Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium

Atezolizumab + Bevacizumab + Pemetrexed Disodium

Atezolizumab + Pemetrexed Disodium

Atezolizumab + Carboplatin + Pemetrexed Disodium

Atezolizumab + Cisplatin + Pemetrexed Disodium

Atezolizumab + Bevacizumab + Cisplatin + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.